Inflammatory Breast Neoplasms  >>  epirubicin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epirubicin / Generic mfg.
NCT00072319: Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Completed
2
US
filgrastim, cyclophosphamide, epirubicin hydrochloride, paclitaxel, adjuvant therapy, neoadjuvant therapy
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Pharmacia, Amgen
Breast Cancer
11/06
11/06
TOP, NCT00162812: Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

Terminated
2
338
Europe
Epirubicin
Jules Bordet Institute, Gustave Roussy, Cancer Campus, Grand Paris, Centre Paul Strauss, Centre Hospitalier du Luxembourg, Clinique Louis Cathy - Baudour - Belgium, HIS - Site Etterbeek - Ixelles - Belgium, Clinique Saint Pierre Ottignies, Clinique Ste Elisabeth - Namur - Belgium, University Hospital of Crete, Feculdade de Medicina da Universidade de Sao Paulo - Brasil
Breast Cancer
12/08
04/09
NCT00756470: Phase II Neoadjuvant in Inflammatory Breast Cancer

Terminated
2
15
US
Lapatinib, Tykerb, GW572016, Paclitaxel, Taxol, 5-Fluorouracil (5-FU), 5-FU, Adrucil, Efudex, Epirubicin, Cyclophosphamide, Cytoxan, Neosar
M.D. Anderson Cancer Center, GlaxoSmithKline
Breast Cancer
10/13
10/13

Download Options